Compare ARVN & ETD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARVN | ETD |
|---|---|---|
| Founded | 2015 | 1932 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Home Furnishings |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 658.2M | 569.7M |
| IPO Year | 2018 | 1996 |
| Metric | ARVN | ETD |
|---|---|---|
| Price | $8.96 | $19.98 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 19 | 1 |
| Target Price | $15.05 | ★ $27.00 |
| AVG Volume (30 Days) | ★ 854.3K | 466.6K |
| Earning Date | 05-04-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 8.15% |
| EPS Growth | ★ 58.84 | N/A |
| EPS | N/A | ★ 1.10 |
| Revenue | $262,600,000.00 | ★ $766,784,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.73 |
| P/E Ratio | ★ N/A | $17.90 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.06 | $18.28 |
| 52 Week High | $14.22 | $31.41 |
| Indicator | ARVN | ETD |
|---|---|---|
| Relative Strength Index (RSI) | 35.45 | 44.74 |
| Support Level | $7.35 | $18.28 |
| Resistance Level | $10.18 | $22.89 |
| Average True Range (ATR) | 0.51 | 0.52 |
| MACD | -0.03 | 0.09 |
| Stochastic Oscillator | 23.34 | 65.58 |
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
Ethan Allen Interiors Inc through its subsidiaries, operates as an interior design company, and a manufacturer and retailer in the home furnishings marketplace. Its product offerings include fabric chairs, beds, wallpapers, desks, and dining tables among others. The company's reportable segments are; Wholesale and Retail. The Wholesale segment is principally involved in the development of the Ethan Allen brand and encompasses all aspects of design, manufacturing, sourcing, marketing, sale, and distribution of home furnishings and accents. The Retail segment which generates maximum revenue, sells home furnishings and accents to clients through company-operated design centers. Geographically, it derives key revenue from the United States and the rest from other regions.